BioAgilytix’s LC/MS global expansion with Lynn Kamen and Dave Beyerlein
In this interview, Lynn Kamen and Dave Beyerlein share insights into BioAgilytix’s (NC, USA) strategic LC/MS expansion in Europe at their bioanalytical laboratory in Hamburg, Germany. The pair discusses the impact this expansion will have on their ability to regionally support clinical trials that need rapid turnaround of samples. Additionally, they delve into approaches their team uses to measure PK for complex therapeutics such as ADCs using LC/MS, along with other modalities where LC/MS plays a critical role.
Questions:
- Why is BioAgilytix expanding their LC/MS capabilities?
- Are there any regulatory considerations for choosing to use LC/MS to analyse the PK of large molecules?
- What applications are LC/MS best suited to support?
- What are the approaches you take to measure PK for ADCs via LC/MS?
- What other modalities can be effectively analyzed using LC/MS?
Lynn Kamen
Scientific Officer, Executive Director
BioAgilytix
Lynn Kamen is a Scientific Officer, Executive Director at BioAgilytix. She received her PhD in Immunology at the University of Michigan (MI, USA) and completed a postdoctoral fellowship in Immunology at the University of California, San Francisco (CA, USA). Lynn is an accomplished scientific leader with over 15 years of experience in drug development, with deep technical expertise across large molecules, small molecules and advanced therapy medicinal products. Her experience spans multiple therapeutic areas, including oncology, cancer immunotherapy, immunology, ophthalmology and neurology.
Dave Beyerlein
Vice President & General Manager, LC/MS Global Lead
BioAgilytix
Dave Beyerlein is the Vice President and General Manager of the BioAgilytix San Diego, California lab and LC/MS Global Lead. With over 30 years of LC/MS experience, he is a Cofounder of MicroConstants (CA, USA), acquired by BioAgilytix in 2021. After joining the BioAgilytix team, Dave has expanded LC/MS services globally to Durham, North Carolina and Hamburg, Germany. Dave also assists with method development and the ongoing LC/MS expansion at 360biolabs (Melbourne, Australia), a BioAgilytix company specializing in PK and PD for early-phase clinical studies.
The opinions expressed in this interview are those of the interviewees and do not necessarily reflect the views of Bioanalysis Zone or Taylor & Francis Group.
In association with:
